Welcome to our dedicated page for Si-Bone SEC filings (Ticker: SIBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SI-BONE, Inc. (NASDAQ: SIBN) files a range of reports with the U.S. Securities and Exchange Commission that provide detailed insight into its sacropelvic-focused medical device business. This SEC filings page brings together those documents and pairs them with AI-powered summaries to help interpret the information that matters for SIBN stock.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, SI-BONE discloses its revenue from sacroiliac joint fusion and related sacropelvic procedures, gross margin, operating expenses, net loss, adjusted EBITDA, cash and investments, and other key financial metrics. These filings also describe risk factors, clinical evidence supporting its technologies, and considerations related to reimbursement, supply chain, and the healthcare operating environment.
Current reports on Form 8-K are used by SI-BONE to announce material events such as quarterly financial results, preliminary unaudited revenue and cash figures, and leadership or board changes. For example, recent 8-K filings have referenced press releases on quarterly results, preliminary full-year revenue, and executive transitions, as well as consulting and retirement agreements with senior leaders and directors.
This page also provides access to other SEC documents that may include registration statements and proxy materials, which can address topics such as equity compensation, board composition, and corporate governance. For investors interested in insider activity, Forms 3, 4, and 5 (when filed) detail transactions by directors and officers in SIBN shares.
AI-generated highlights on this platform are designed to make SI-BONE’s filings easier to navigate by surfacing key figures, summarizing management’s discussion of performance, and pointing to sections that discuss sacropelvic technologies, clinical evidence, and reimbursement dynamics. Real-time updates from EDGAR ensure that new 10-K, 10-Q, and 8-K filings for SI-BONE, Inc. are available promptly, while AI summaries help reduce the time required to understand their implications.
Champlain Investment Partners, LLC reported beneficial ownership of 2,108,944 shares of SI-BONE, Inc. common stock, representing 4.9% of the class as of 09/30/2025. Champlain has sole voting power over 1,337,489 shares and sole dispositive power over 2,108,944 shares, with no shared voting or dispositive power.
The firm files as an institutional investment adviser and certifies that the shares were acquired and are held in the ordinary course of business, not for the purpose or effect of changing or influencing control of SI-BONE, Inc.
SI-BONE, Inc. director Jeffrey W. Dunn reported a small sale of company stock tied to tax obligations. On February 2, 2026, he sold 337 shares of common stock at a weighted average price of $16.4157 per share.
The footnotes explain this was a mandatory "sell to cover" transaction to satisfy tax withholding from vesting restricted stock units, and not a discretionary trade. After the sale, Dunn beneficially owned 9,970 shares directly, including 9,491 shares issuable upon settlement of restricted stock units, and 80,115 shares indirectly held by The Jeffrey W. Dunn Living Trust Dated May 17, 2012.
SI-BONE director Jeffrey W. Dunn, through The Jeffrey W. Dunn Living Trust Dated May 17, 2012, reported selling 20,000 shares of SI-BONE common stock on January 8, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan dated May 7, 2025 at a weighted-average price of $21.2753 per share, with individual trade prices ranging from $20.84 to $21.84.
Following the sale, the trust held 80,115 shares indirectly, while Dunn also had 10,307 shares directly, including shares issuable upon settlement of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of SI-BONE common stock.
SI-BONE, Inc. filed a current report describing that it has released a press release with preliminary unaudited revenue and cash and equivalents figures for the fourth quarter and full year 2025. These early numbers are meant to give the market an initial view of the company’s recent performance and year-end liquidity before audited results are available.
The company also plans meetings with investors and analysts, supported by a slide presentation. Both the press release and the presentation are included as exhibits and are being furnished, not filed, which means they are not automatically incorporated into other securities law filings.
SIBN received a notice that an affiliated holder plans to sell common stock under Rule 144. The filing covers a proposed sale of 60,000 common shares, to be executed through Morgan Stanley Smith Barney LLC on or around January 8, 2026 on the NASDAQ market. These 60,000 shares were acquired as restricted stock units from the issuer on October 15, 2021.
Recent trading history in the notice shows that The Jeffrey W. Dunn Living Trust has already sold common shares in the past three months, including 20,000 shares for gross proceeds of
SI-BONE, Inc. executive reports tax-related share sale
SI-BONE, Inc. Senior Vice President, Operations & Administration and Chief Legal Officer Michael A. Pisetsky reported selling small amounts of the company’s common stock on January 2, 2026. The sales, executed in three trades at prices of $19.75, $19.6811, and $19.5788 per share, were made to cover tax withholding obligations tied to the vesting of restricted stock units. According to the disclosure, this was a mandated “sell to cover” transaction and not a discretionary trade.
After these sales, Pisetsky beneficially owned 228,436 shares of SI-BONE common stock directly. This amount includes 119,679 shares that are issuable upon settlement of restricted stock units, each unit representing the right to receive one share of common stock.
SI-BONE, Inc. director Jeffrey W. Dunn reported a series of transactions in the company’s common stock. On December 8, 2025, he exercised a stock option for 1,241 shares at an exercise price of $4.32 per share and acquired those shares.
That same day, he sold 1,241 shares of common stock and separately sold another 18,759 shares, both reported with a weighted-average sale price of $19.3297 per share, with individual sale prices ranging from $19.13 to $19.85. The sales were made under a Rule 10b5-1 trading plan dated May 7, 2025. After these transactions, he beneficially owned 10,307 shares directly, including shares issuable on settlement of restricted stock units, and 110,115 shares indirectly through The Jeffrey W. Dunn Living Trust dated May 17, 2012.
SI-BONE, Inc. (SIBN)400 shares of common stock at $20 per share, reported with transaction code "S" for a sale. The filing notes that this trade was made under a Rule 10b5-1 trading plan dated June 13, 2025, which is a pre-arranged plan for selling shares.
After this transaction, the reporting person beneficially owned 251,496 shares of SI-BONE common stock. This total includes 125,823 shares issuable upon settlement of restricted stock units, where each unit represents the right to receive one share of common stock.
SI-BONE, Inc. (SIBN) filed a Form 4 reporting stock sales by its Chief Financial Officer, Anshul Maheshwari. The CFO sold 1,200 shares of common stock on 11/21/2025 at a weighted-average price of about $20.0133 per share and an additional 100 shares on 11/25/2025 at $20.00 per share. These sales were made under a pre-arranged Rule 10b5-1 trading plan dated December 13, 2024, which is designed to allow insiders to sell stock according to a set schedule.
Following these transactions, Maheshwari beneficially owns 203,773 shares of SI-BONE common stock. This total includes 143,116 shares issuable upon settlement of restricted stock units, each representing a right to receive one share of common stock.
SI-BONE, Inc. (SIBN)11/17/2025, he sold 1,707 and 2,126 shares of common stock in two transactions at weighted average prices of $17.4232 and $17.4462, respectively. These sales were made to cover tax withholding obligations arising from the vesting of restricted stock units and are described as non-discretionary “sell to cover” trades.
Following these transactions, the reporting person beneficially owned 268,144 shares of SI-BONE common stock, including 133,316 shares issuable upon settlement of restricted stock units, with each unit representing a contingent right to receive one share.